Despite all the setbacks, Boston Scientific won’t stop pushing the Watchman.
The medical-device giant committed hundreds of millions to acquire the tiny heart implant more than a decade ago, and then endured a years-long debate at the Food and Drug Administration over whether to approve it.
When that approval finally came through, for a limited pool of patients, Boston Scientific was prepared with a plan for something much larger.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source: www.statnews.com
